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Summary
We present evidence for a specific role of p53 in the
mitochondria-associated cellular dysfunction and be-
havioral abnormalities of Huntington’s disease (HD).
Mutant huntingtin (mHtt) with expanded polyglutam-
ine (polyQ) binds to p53 and upregulates levels of
nuclear p53 as well as p53 transcriptional activity in
neuronal cultures. The augmentation is specific, as it
occurs with mHtt but not mutant ataxin-1 with ex-
panded polyQ. p53 levels are also increased in the
brains of mHtt transgenic (mHtt-Tg) mice and HD pa-
tients. Perturbation of p53 by pifithrin-, RNA inter-
ference, or genetic deletion prevents mitochondrial
membrane depolarization and cytotoxicity in HD cells,
as well as the decreased respiratory complex IV
activity of mHtt-Tg mice. Genetic deletion of p53
suppresses neurodegeneration in mHtt-Tg flies and
neurobehavioral abnormalities of mHtt-Tg mice. Our
findings suggest that p53 links nuclear and mitochon-
drial pathologies characteristic of HD.
Introduction
Huntington’s disease (HD) is a genetically dominant
neurodegenerative disease caused by a mutation in the
huntingtin gene leading to an abnormal Huntingtin pro-
tein product (Htt) (The Huntington’s Disease Collabora-
tive Research Group, 1993). Mutant Htt protein (mHtt)
contains elongated polyglutamines (polyQ) whose length
correlates with an earlier age of disease onset (Ross,
2002; Sawa, 2001; Tobin and Signer, 2000). Expression
of mHtt, especially N-terminal fragments, elicits cyto-
toxicity in cell models (Cooper et al., 1998; Hackam et
al., 1998; Wellington et al., 2000) as well as fly models
(Jackson et al., 1998; Marsh et al., 2000) and elicits*Correspondence: asawa1@jhmi.edubehavioral abnormalities in mice (Carter et al., 1999;
Hodgson et al., 1999; Reddy et al., 1998; Schilling et
al., 1999), suggesting that the pathophysiology of HD
involves a toxic gain of function.
The pathophysiology of HD has been linked to mito-
chondrial dysfunction (Grunewald and Beal, 1999; Sawa,
2001; Schapira, 1997). Mitochondrial enzyme activities
of the respiratory chain complexes II/III and IV are im-
paired specifically in the caudate and putamen of HD
patient brains (Browne et al., 1997; Tabrizi et al., 1999)
and striatum of mHtt transgenic (mHtt-Tg) mice (Tabrizi
et al., 2000). 3-Nitropropionic acid (3-NPA), a selective
mitochondrial toxin for the complex II, elicits striatal
damage resembling HD (Beal et al., 1993). Mitochon-
drial disturbances in HD patient brains are not likely
secondary to overall neuropathologic alterations, as
lymphoblasts from HD patients manifest abnormal mito-
chondrial membrane depolarization (Panov et al., 2002;
Sawa et al., 1999). The mitochondrial defect may be
disease specific, as lymphoblasts from the patients
with spinocerebellar ataxia type 1 (SCA1), another neu-
rodegenerative condition caused by an expanded polyQ
in the disease gene ataxin-1, do not display mitochon-
drial membrane depolarization (Sawa et al., 1999).
Nuclear disturbances are also implicated in HD
(Hodgson et al., 1999; Peters et al., 1999; Saudou et al.,
1998; Schilling et al., 2004; Steffan et al., 2000; Wheeler
et al., 2000). In both HD cell and transgenic animal
models, nuclear accumulation of mHtt strongly en-
hances neurotoxicity. Mutant Htt interacts with nuclear
factors such as CREB binding protein (CBP) (Nucifora
et al., 2001) and Sp1/TAFII130 (Dunah et al., 2002),
whose loss of function may mediate cytotoxicity.
The tumor suppressor gene p53 has multiple func-
tions in processes as diverse as angiogenesis and che-
motaxis (Vogelstein et al., 2000). p53 is also expressed
in the central nervous system (CNS), where its function
is not established (Morrison and Kinoshita, 2000). While
acute excitotoxic insults, such as kainic acid, induce
p53 activation and p53 null mice are mildly resistant
to neurotoxicity (Morrison et al., 1996), it is unclear
whether the increase of p53 is primary or secondary
to excitotoxicity. Overexpression of p53 in dissociated
primary neuron cultures elicits neuronal death (Jordan
et al., 1997), but the role of endogenous p53 has not
been investigated. Binding of mHtt with p53 has been
reported (Steffan et al., 2000), but its pathophysiologi-
cal implication remains unknown. Immortalized striatal
neurons derived from mHtt knockin mouse embryos
show elevated levels of p53 protein (Trettel et al., 2000).
Genes regulated by p53 are among a large cohort
upregulated in cell cultures transfected with mHtt (Sipi-
one et al., 2002).
Although nuclei and mitochondria participate in HD
pathology, their relationship has been elusive. Because
nuclear p53 regulates many mitochondrial genes and
genes for oxidative stress (Sharpless and DePinho,
2002; Vogelstein et al., 2000), we hypothesized that p53
might link the nuclear and mitochondrial pathologies
in HD.
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30Figure 1. mHtt Upregulates p53
(A) Immunoblotting shows that p53 protein level is increased significantly in the P1 fraction of PC12 cells stably expressing the N-terminal 63
amino acids of Htt with 148 polyglutamine (N63-148Q), but not the cells expressing N63-18Q, after 5 days of induction. Inhibition of N63-
148Q induction is not associated with p53 upregulation.
(B) p53 mRNA level is only marginally changed by mHtt, as shown by reverse Northern dot blotting. The mRNA expression ratios in cells with
N63-148Q to those with N63-18Q are 132% (β-actin), 86% (zif268), 81% (Fos-B), 100% (H2O), 143% (p53), and 296% (Siah).
(C) p53 protein level is increased both in 1% SDS-soluble and -insoluble fractions of PC12 cells stably expressing Htt N63-148Q, which is
shown by immunoblotting.
(D) Increased p53 protein level is evident in immunoblotting from the whole-cell lysates of striatum of 8-month-old mHtt-Tg mouse expressing
the N-terminal 171 amino acids of Htt with 82 polyglutamine (N171-82Q), compared to wild-type (WT) littermate. Injection of kainate elicits a
lesser increase of p53 than mHtt. n = 3 per each group.
(E) p53 is increased in whole tissue lysates of postmortem cerebral cortex and striatum of HD patients, which is shown by immunoblotting.
The increase in p53 protein level is greater in cases with higher grades of HD pathology. No increase of p53 by mHtt is evident in the
cerebellum. C, control (n = 3 per each grade).
(F) p53 directly binds to Htt. His-Htt N171-23Q or -120Q, and GST-p53 purified from bacteria were incubated in PBS containing 1% Triton
X-100. His-Htt bound to GST-p53 was analyzed by immunoblotting.
(G and H) Expansion of polyQ strengthens the interaction between exogenous Htt and p53. Co-IP of Htt and p53 was examined in 293T cells
transfected with (G) N-terminal Htt (N171-23Q-myc or N171-148Q-myc) or (H) full-length Htt (FL-23Q or FL-82Q).
(I) In HD lymphoblasts treated with staurosporine, endogenous p53 and Htt interact, which is evidenced by coprecipitation of Htt with p53 by
an anti-p53 antibody, but not by IgG.
All the figures represent two to three independent experiments. The results of the experiments in (E)–(H) are quantified in arbitrary units,
where 1 equals to level of control or wtHtt.
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31Figure 2. mHtt Increases p53-Mediated Transcription
(A) Stably transfected N63-148Q increases p53 transactivation 4-fold in PC12 cells compared to N63-18Q (t test: *p < 0.0005).
(B) Transiently transfected N171-82Q increases p53 transactivation 5-fold in rat primary cortical neurons compared to N171-18Q (t test:
**p < 0.0001).
(C) Unlike N171 and full length (FL) Htt, transiently transfected ataxin-1 does not increase p53 transcription activity, (t test: *p < 0.0005).
(D) RNAi to p53 (pSuper-p53) knocks down p53 protein, whereas control RNAi (pSuper-control) does not.
(E) RNAi to p53 and pifithrin-α (PFT-α) effectively inhibit p53-mediated transcription (t test: *p < 0.0005).
(F) p53 target proteins are significantly augmented by mHtt. Apaf-1, Bax, and Puma levels were examined in PC12 cells transiently transfected
with Htt N171-18Q or N171-82Q 90 hr after transfection. Bax and Puma protein levels were augmented 4-fold and 6-fold, respectively, whereas
Apaf-1 level was only marginally changed.
All the graphs show mean ± SEM of three independent experiments performed in triplicate.We have investigated p53 in HD cell and transgenic
animal models expressing mHtt as well as HD patient
brains. We present evidence for a specific role of p53
in the mitochondria-associated cellular dysfunction and
behavioral abnormalities of Huntington’s disease.
Results
Mutant Htt Upregulates Nuclear p53 Levels
and Transcription Activity
In PC12 cells stably expressing the N-terminal 63 amino
acids of Htt with 148 polyQ (N63-148Q) in an inducible
manner (Igarashi et al., 2003), the protein level of p53
is increased more than 10-fold after induction of mHtt,
but not wild-type Htt (wtHtt) N63-18Q. The increased
p53 occurs selectively in the P1 fractions designated
as crude nuclei (Figure 1A) in 1% SDS-soluble, nonag-
gregate fractions (Figure 1C), implying that the transac-
tivation-independent role for p53 in the mitochondria is
unlikely (Chipuk et al., 2004). The increase of p53 pro-
tein appears to be posttranslational, as mRNA levels of
p53 are increased only 1.4-fold (Figure 1B). In the brains
of transgenic mice expressing the N-terminal 171 amino
acids of Htt with 82 polyglutamine repeats (N171-82Q)(Schilling et al., 1999), p53 is also elevated (Figure 1D).
Enhancement of p53 is selective, as kainate, which
causes more neuronal death than mHtt, induces a lesser
increase in p53. Postmortem brains of human HD pa-
tients also manifest substantial p53 increases, with the
highest levels in the cases with the most extensive HD
pathology (Figure 1E). Only striatum and cerebral cor-
tex show p53 upregulation with no increase in cerebel-
lum, fitting with the regional and cellular selectivity of
HD pathology (Sawa, 2001; Sisodia, 1998; Tobin and
Signer, 2000).
Confirming the previously reported interaction be-
tween exon 1 of Htt (N63-20Q, -51Q, and -83Q) and p53
(Steffan et al., 2000), we observe direct binding of Htt
N171 and p53 in vitro (Figure 1F). Furthermore, p53
coimmunoprecipitates with N171 as well as full-length
(FL) Htt in transiently transfected 293T cells (Figures 1G
and 1H). In both cases, mHtt binds more efficiently to
p53 than wtHtt. Coimmunoprecipation (co-IP) of p53
and Htt at endogenous protein levels is evident in
stressed HD patient lymphoblasts (Figure 1I).
We wondered whether augmented p53 is associated
with increased transcriptional activity. Using the p53
binding sequence upstream of a luciferase reporter
gene (el-Deiry et al., 1992), we monitored p53-mediated
Neuron
32Figure 3. Suppression of p53 Reverses mHtt-Elicited Mitochondrial Depolarization
(A) Pretreatment with 10 M pifithrin-α (PFT-α) reverses mitochondrial depolarization in 25 M cyanide-exposed HD patient lymphoblasts (82
polyQ). In response to cyanide, only HD, but not control (18 polyQ), lymphoblasts manifest robust mitochondrial depolarization (t test:
**p < 0.0001).
(B and C) Suppression of p53 by PFT-α reverses mitochondrial depolarization elicited by N63-148Q in PC12 cells. Cells were evaluated on
the fifth day of induction. JC-1 produces a red signal from polarized mitochondria and green from depolarized mitochondria. Mitochondria
are polarized in PC12 cells expressing N63-18Q and depolarized in cells with N63-148Q, reflecting initiation of cell death, which is reversed
by pifithrin-α. Pifithrin-α does not protect the cells from rapid mitochondrial depolarization by FCCP, an uncoupler of mitochondrial respiration
Each graph bar corresponds to the scoring of about 500 PC12 cells from randomly chosen fields (t test: **p < 0.0001, *p < 0.005).
(D and E) Genetic deletion of p53 prevents mitochondrial depolarization by N171-82Q in mouse primary cortical neurons. After 72 hr incubation
p53 in Huntington’s Disease
33ratory chain IV (Tabrizi et al., 2000). To evaluate the influ- type compound eyes contain w800 ommatidia, each of
of Htt with GFP, changes in mitochondrial membrane potential were measured using red emission of a fluorescent indicator, Mitotracker.
N171-82Q causes mitochondrial depolarization in p53+/+ but not in p53−/− neurons. Cell death is not evident at 72 hr, as shown by long
neurites (GFP) and round nuclei (Hoechst). Each graph bar corresponds to the scoring of about 1000 to 2000 neurons from randomly chosen
fields (t test: **p < 0.0001, *p < 0.001).
(F) Specific activity of mitochondrial respiratory chain complex IV, cytochrome C oxidase, is decreased in mHtt-Tg mouse striatum, which is
significantly reversed by daily i.p. administration of pifithrin-α. Four brains per group were analyzed (t test: *p < 0.01, **p < 0.005). All the
graphs and figures represent two to three independent experiments. Bars show mean ± SEM.gene activation (Figures 2A and 2B). Stable expression
of mHtt N63-148Q in PC12 cells elicits a 4-fold increase
of p53 transcriptional activation, while in rat primary
cortical cultures, transient transfection of mHtt N171-
82Q causes an approximately 5-fold amplification of
p53 activity. Activation is selective for N171-82Q as well
as FL mHtt, since transient expression of ataxin-1 with
expanded polyQ fails to influence p53 transcriptional
activity (Figure 2C). Vector-based RNA interference
(RNAi) to p53 (pSuper-p53) (Brummelkamp et al., 2002)
and a specific p53 inhibitor, pifithrin-α (1 M) (Duan et
al., 2002; Komarov et al., 1999), both block mHtt-
induced p53 transactivation (Figures 2D and 2E). We
compared protein levels of three p53 targets that di-
rectly associate with mitochondria, Apaf-1 (Sang et al.,
2005), Bax (Miyashita and Reed, 1995), and Puma (Yu et
al., 2001), in Htt-transfected PC12 cells. Bax and Puma
protein levels are significantly augmented by mHtt,
whereas Apaf-1 is only marginally augmented (Fig-
ures 2F).
Augmented p53 Mediates Mitochondrial Dysfunction
in HD Cell and Transgenic Animal Models
Mitochondrial membrane depolarization is enhanced in
lymphoblasts of HD but not SCA1 patients treated with
low concentrations of cyanide (25 M) (Sawa et al.,
1999). As p53 can mediate mitochondrial function and
is selectively influenced by mHtt but not by mutant
ataxin-1 (Figure 2C), we explored a role for p53 in mHtt-
mediated mitochondrial dysfunction.
Pretreatment of the cyanide-exposed HD lympho-
blasts with 10 M pifithrin-α blocks depolarization of
the mitochondria (Figure 3A). Induction of mHtt N63-
148Q in PC12 cells causes pronounced mitochondrial
membrane depolarization after 5 days of induction (Fig-
ures 3B and 3C). Treatment with pifithrin-α (1 M) com-
pletely blocks the depolarization, indicating that p53
mediates the mitochondrial abnormality. By contrast,
pifithrin-α does not affect the rapid mitochondrial mem-
brane depolarization elicited by carbonylcyanide p-(tri-
fluoromethoxy) phenylhydrazone (FCCP), a protonophore
and uncoupler of oxidative phosphorylation in mitochon-
dria, demonstrating specificity of pifithrin-α for the p53
pathway.
In primary cortical cultures of p53+/+ mice, we ob-
serve substantial mitochondrial membrane depolariza-
tion associated with transfected mHtt N63-148Q but
not wtHtt N63-18Q at a time when nuclei are intact
in most neurons (Figures 3D and 3E). Cultures from
p53+/− and p53−/− mice (Donehower et al., 1992) are
protected from this mitochondrial depolarization.
mHtt-Tg mouse models display mitochondrial dys-
function affecting enzymes in the mitochondrial respi-ence of p53 on such mitochondrial dysfunction in vivo,
we injected line 81 N171-82Q mHtt-Tg mice i.p. with
pifithrin-α, which efficiently crosses the blood-brain
barrier (Duan et al., 2002). The treatment significantly
prevents impaired complex IV activity of mHtt-Tg mice
(Figure 3F).
p53 Mediates mHtt Cytotoxicity, Independent
of Nuclear Aggregate Formation
To address the cellular consequences of mitochondrial
dysfunction, we evaluated cytotoxicity following inhibi-
tion of p53 with pifithrin-α, RNAi, or genetic deletion.
Induction of mHtt N63-148Q (Igarashi et al., 2003) or
transfection of FL-82Q causes the death of PC12 cells.
The tripling of PC12 cell death elicited by mHtt is abol-
ished by pifithrin-α (10 M) or pSuper-p53 (Figure 4A).
Antisense oligonucleotides against p53 provide about
the same degree of protection as pifithrin-α (data not
shown).
We also employed primary cerebral cortical cultures
from wild-type and p53-deleted mice. In p53+/+ cul-
tures, mHtt N171-82Q transfection elicits 2.5 times
greater cell death than wtHtt N171-18Q. By contrast,
mHtt fails to elicit neurotoxicity in cultures from p53−/−
mice. Pronounced, but not complete, protection is also
evident in p53+/− cultures (Figures 4B and 4C).
We investigated whether p53 is also involved in mHtt-
associated aggregate formation (DiFiglia et al., 1997),
whose role in HD pathogenesis is controversial (Arrasate
et al., 2004; Sisodia, 1998). We monitored the formation
and nuclear targeting of mHtt aggregates in cortical cul-
tures (Figures 4D and 4E). We find no significant differ-
ence between p53+/+ and p53−/− neurons in aggregate
formation and nuclear localization of mHtt. We observe
substantial nuclear fragmentation and condensation in
p53+/+ but not in p53−/− preparations of mHtt cells.
Thus, in contrast to the critical role of p53 in mitochon-
drial membrane depolarization and cell death, mHtt-
associated nuclear aggregate formation does not ap-
pear to be influenced by p53.
Deletion of p53 Suppresses mHtt-Induced Retinal
Degeneration in Drosophila
To explore the role of p53 in mHtt-induced cell death of
intact animals, we evaluated the effect of p53 deletion
in mHtt-Tg flies (Jackson et al., 1998). The mHtt-Tg
flies, which express mHtt N170-120Q under the control
of the eye-specific expression GMR promoter (Hay et
al., 1994), manifest prominent cell death of photorecep-
tor neurons. We crossed mHtt-Tg flies with p53 mutant
flies in which the p53 gene was deleted by homologous
recombination (Rong et al., 2002) and assessed the ef-
fects of deleting p53 in the compound eyes. Wild-
Neuron
34Figure 4. Suppression of p53 Reverses Cell Death by mHtt
(A) Suppression of p53 prevents toxicity by mHtt in PC12 cells. Pifithrin-α (PFT-α) prevents N63-148Q toxicity on the 8th day of induction (the
left panel). RNAi to p53 blocks N171-82Q and FL-82Q toxicity 4–8 days after transient transfection (the right panel). (t test: *p < 0.001).
(B and C) Mouse primary cortical neurons nullizygous for p53 are resistant to N171-82Q toxicity. Htt was cotransfected with GFP on 4 DIV,
and toxicity was measured after 96 hr of incubation. Neuronal degeneration was assessed by neurite loss and nuclear shrinkage. (Inset)
Hoechst nuclear staining (B). Homozygous deletion of p53 reverses mHtt-mediated cellular toxicity in cortical neurons. Pronounced protection
is also evident in p53+/− cultures (t test: **p < 0.0001, *p < 0.001).
(D and E) p53 does not affect mHtt aggregate formation. N67-104Q tagged with GFP (N67-104Q-GFP) was transfected into cortical neurons
on 4 DIV. Nuclei are shown in blue by Hoechst staining. N67-104Q-GFP is pseudocolored in red. All the transfected neurons develop nuclear
or cytoplasmic mHtt aggregates after 2 days of incubation, regardless of p53 genotype. Nuclear fragmentation reflecting apoptosis is evident
in p53+/+ neurons but absent in p53−/−.
All the graphs and figures represent four independent experiments. Bars show mean ± SEM. Each graph bar corresponds to the scoring of
about 1000 to 2000 neurons or 500 PC12 cells from randomly chosen fields.
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plane of section. The photoreceptor cells contain a mi-
crovillar structure referred to as the rhabdomere. Wild-
type (wt) and p53 knockout flies (p53) display a normal
composition of seven photoreceptor cells in each om-
matidium (Figure 5). mHtt-Tg flies (Htt), however, mani-
fest strong age-dependent loss of rhabdomeres and
photoreceptor cells, as reported previously (Jackson et
al., 1998) (Figure 5). Deletion of two copies of p53 in
mHtt-Tg flies (Htt;p53) suppresses this phenotype, as
shown using the optical neutralization technique on in-
tact heads and in Toluidine blue-stained sections (Fig-
ure 5). Thus, p53 mediates mHtt-induced neurotoxicity
in intact organisms.
p53 Modulates Neurobehavioral Abnormalities
in HD Transgenic Mouse Models
Mutant Htt transgenic mice manifest several neuro-
behavioral abnormalities, presumably reflecting abnor-
malities in cortico-striato-pallido-thalamo-pontine neu-
ral pathways: clasping of the limbs, augmented circling
behavior, impaired prepulse inhibition, and poor perfor-
mance in rotarod tests (Braff et al., 2001; Carter et al.,
1999; Hebb and Robertson, 1999; Hodgson et al., 1999;
Reddy et al., 1998; Schilling et al., 1999). Prepulse inhi-
bition of startle reflexes is also disordered in HD pa-
tients (Swerdlow et al., 1995). The rotarod paradigm is
a widely used measure of motor coordination in HD
mouse models. However, impairment in the rotarod test
may not necessarily reflect striatal dysfunction, be-
cause mice with cerebellar deficits or muscle relaxation
perform poorly in rotarod testing (Crawley, 2000).
To address a possible role for p53 in mHtt-Tg mice be-
havior, we genetically deleted the two alleles of p53 in
line 81 of mHtt-Tg mice overexpressing N171-82Q (Schil-
ling et al., 1999) by cross-breeding with p53 knockout
mice.
When suspended by the tail, wild-type and p53−/−Figure 5. Genetic Deletion of p53 Diminishes Retinal Degeneration in mHtt-Tg Drosophila
(A) Time course of photoreceptor degeneration determined by the optical neutralization technique. GMR-driven mHtt N170-120Q causes age-
dependent retinal degeneration in Drosophila (Htt). Genetic deletion of p53 provides substantial, but not complete, protection from degenera-
tion (Htt;p53). No photoreceptor cell loss is observed in wild-type (wt) and p53 knockout (p53) flies. Each point shows the mean ± SD.
(B) Representative photomicrographs of ommatidia using the optical neutralization (the upper panel) and Toluidine blue-stained semithin
sections (the lower panel) from wt, p53, Htt, and Htt;P53 flies at 4 days posteclosion.mice display escape reflexes (hindlimbs spread), whereas
mHtt-Tg mice promptly clasp their hindlimbs (Sanchez
et al., 2003; Schilling et al., 1999). In mHtt-Tg/p53−/−
mice, this motor dysfunction is ameliorated (Figures 6A
and 6B).
We observe a pronounced increase in a clockwise
rotational behavior of 3- to 3.5-month-old line 81 mHtt-
Tg mice in the open field test, as reported in other types
of mHtt-Tg mice (Hodgson et al., 1999; Reddy et al.,
1998) (Figure 6C). The increased rotation is selective,
because time spent in the corner, reflecting “anxiety”
(Crawley, 2000), as well as vertical exploratory move-
ments are not affected in mHtt-Tg mice (data not
shown). By contrast, rotation is not increased in mHtt-
Tg/p53−/− mice (Figure 6C).
Startle responses to a loud 120 dB noise are inhibited
by prior exposure of wild-type and p53−/− mice to a
2–4 dB noise. As observed with another line of mHtt-
Tg mice (Carter et al., 1999), our mHtt-Tg mice display
a 50%–65% decrease in this prepulse inhibition. This
abnormality is not evident in mHtt-Tg/p53−/− mice (Fig-
ure 6D).
Confirming earlier work (Carter et al., 1999; Hodgson
et al., 1999; Reddy et al., 1998; Schilling et al., 1999),
mHtt-Tg mice display rotarod performance deficits,
which are reversed in mHtt-Tg/p53−/− mice (Figure 6E).
Expression of mHtt N171-82Q in mHtt-Tg mice is
under the control of mouse prion protein promoter
(MoPrP) (Schilling et al., 1999) and not affected by ge-
netic deletion of p53 (Figure 6F). Body weights of mHtt-
Tg mice are unaffected by p53 deletion (Figure 6G).
Normalization of neurobehavioral deficits of mHtt-Tg
mice by genetic deletion of p53 indicates a role for p53
in the expression of these disturbances.
Discussion
In this study, we present evidence favoring a specific
role for p53 in HD pathology. Mutant Htt binds p53 and
Neuron
36Figure 6. Genetic Deletion of p53 Reverses
Behavioral Abnormalities in mHtt-Tg mice
(A and B) Deletion of p53 increases latency
to clasping of the hindlimbs in mHtt-Tg mice.
The latency was measured up to 3 min.
(C) Hyperactivity in rotational movement of
3- to 3.5-month-old mHtt-Tg mice is normal-
ized by deletion of p53. Bars show the num-
ber of clockwise rotations for 20 hr in open-
field test machines.
(D) Impairment of prepulse inhibition of the
acoustic startle response in mHtt-Tg mice is
reversed by deletion of p53. Bars indicate
prepulse inhibition of mice responding to
acoustic stimuli of 120 dB with 100 ms pre-
pulse warning stimuli of 4 dB above back-
ground noise.
(E) Rotarod performance is impaired in mHtt-
Tg mice, which is reversed by p53 deletion.
Bars indicate mean latency to fall on the ac-
celerating rotarod ± SEM (from 4 rpm to 40
rpm over 10 min).
(F) By cross-breeding with p53 knockout
mice, the levels of mouse prion promoter
(MoPrP)-driven mHtt in mHtt-Tg mice are
not altered.
(G) Body weights of mHtt-Tg mice are unaf-
fected by p53 deletion.
All the graphs represent two independent
experiments (one-way ANOVA: *p < 0.05). Six
or seven mice were used for each genotype.elicits increases in the levels of p53 protein in the nu- s
tcleus and p53 transcriptional activity. These elevations
occur in PC12 cells, primary neuronal cultures, mHtt- S
aTg mice, and postmortem brains of HD patients. Pertur-
bation of p53 by pifithrin-α, RNAi, or genetic deletion b
iprevents mHtt-induced cellular dysfunction and abnor-
mal behavior in vivo. Mitochondrial membrane depolar- l
sization and cytotoxicity by mHtt is prevented by inhibition
of p53. By contrast, mHtt nuclear and cytoplasmic aggre- l
(gates are not influenced by p53 deletion. Genetic deletion
of p53 suppresses mHtt-induced neurodegeneration in h
pDrosophila. Some of the neurobehavioral defects in mHtt-
Tg mice, including dyskinesia of the hindlimbs, rotational t
pactivity, prepulse inhibition, and rotarod performance, are
prevented by genetic deletion of p53. T
o
pIncreased Nuclear p53 Selectively Elicited by mHtt
We show that Htt and p53 bind in 293T cells trans- d
fected with N171 or FL Htt (Figures 1G and 1H) and in
HD patient lymphoblasts (Figure 1I), consistent with p
tin vitro binding of p53 and Htt (Figure 1F) (Steffan et
al., 2000). The binding of Htt and p53 is augmented by s
pexpansion of polyQ (Figures 1F–1H). Conceivably, mHtt
disturbs interactions of p53 with its regulatory proteins, d
tsuch as MDM2, resulting in stabilization of p53. There
is precedence for modulation of p53 function by influ- r
eencing p53-MDM2 interactions, such as the stabiliza-
tion of p53 by HIF-1α (Chen et al., 2003). c
nThe stabilization and augmentation of p53 by mHtt
appears to be selective and not a general toxic effect of
pexpanded polyQ. Thus, mutant ataxin-1 with the same
polyQ length fails to influence p53-mediated gene tran- tcription. p53 deletion does not affect the impaired mo-
or coordination or reduced Purkinje cell number in
CA1 mice, though some later pathological features
re slightly improved (Shahbazian et al., 2001). Contrast
etween SCA1 and mHtt-Tg mice may reflect p53-
nduced mitochondrial dysfunction in the pathology. HD
ymphoblasts are highly susceptible to cyanide- or
taurosporine-induced mitochondrial membrane depo-
arization, while SCA1 and control lymphoblasts are not
Sawa et al., 1999). Consistent with this observation, we
ave recently observed that UVB irradiation induces the
53 signaling cascade selectively in the fibroblasts of
he patients with HD, but not in those with the other
olyQ diseases, including SCA1 (unpublished data).
he specificity of p53 in HD is further supported by the
bservation that kainate induces a lesser increase in
53 than mHtt, even though it causes more neuronal
eath.
In mHtt-expressing cells, we observe increases of
53-mediated gene expression and some downstream
argets of p53 at the protein level. In contrast, Thomp-
on and colleagues (Steffan et al., 2000) reported re-
ression of p53-regulated promoters by mHtt in a p53-
eficient human osteogenic sarcoma cell line, SAOS-2,
ransfected with exogenous p53. The two contradictory
esults are difficult to compare because, in the pres-
nce of mHtt, exogenous p53 in osteogenic sarcoma
ells may behave differently from endogenous p53 in
eurons.
Nuclear dysfunction has been implicated in HD
athophysiology. Besides p53, other nuclear transcrip-
ional factors such as CBP (Nucifora et al., 2001), Sp1
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37(Dunah et al., 2002), and TAFII130 (Shimohata et al.,
2000) may be involved in HD pathogenesis. For CBP,
Sp1, and TAFII130, loss of function is associated with
mHtt, though these studies employed cultured cells
without evidence for abnormal function in intact ani-
mals. By contrast, our findings link gain of p53 function
with HD in cellular and animal models as well as HD
autopsy brains.
Mitochondrial Dysfunction Mediated by p53 in HD
What downstream pathways might mediate mHtt-p53-
associated disturbances of mitochondrial function?
p53 induces the expression of some downstream tar-
gets, such as Bax and Puma, which may lead to mito-
chondrial membrane depolarization (Vogelstein et al.,
2000), at least in HD cell models. p53 may also regulate
reactive oxygen species (ROS) levels through p66SHC
(Sharpless and DePinho, 2002). ROS inhibit Fe-S clus-
ter-containing enzymes, such as aconitase, and mito-
chondrial respiratory complexes, especially II/III and IV
in HD brains (Grunewald and Beal, 1999). These distur-
bances can elicit mitochondrial membrane depolariza-
tion, which is evident in the neurons expressing mHtt
and HD lymphoblasts.
Mitochondrial abnormalities lead to elevation of intra-
cellular calcium concentration, which is evident in
mHtt-Tg mice (Hansson et al., 2001; Hodgson et al.,
1999). In PC12 cells expressing mHtt, we observe ele-
vated intracellular calcium levels that are lowered by
the p53 inhibitor pifithrin-α (B.-I.B., S.H.S. and A.S., un-
published data). Elevated cytosolic calcium can elicit
several cellular alterations, including overactivation of
the calcium-dependent protease calpain. Interestingly,
cleavage of Htt by calpain is reported in HD brains
(Gafni and Ellerby, 2002; Kim et al., 2001). Abnormal
calcium homeostasis may link altered synaptic func-
tions and excitotoxicity with HD mitochondrial dysfunc-
tion (Grunewald and Beal, 1999). In mHtt-Tg mice,
increased calcium influx via medium spiny neuron-spe-
cific NR1A/NR2B-subtype NMDA receptors disturbs in-
tracellular calcium homeostasis (Zeron et al., 2002),
which can depolarize mitochondria primarily or sec-
ondarily. p53, synergistically upregulated by mHtt and
excitotoxicity, may serve as a modulator of excitotoxi-
city-induced calcium abnormalities. Indeed, NMDA re-
ceptor-mediated death of striatal neurons is selectively
amplified in mHtt-Tg mice (Zeron et al., 2002).
Influence of p53 in HD Pathogenesis In Vivo
We have shown that p53 plays a specific role in HD
pathology by using mHtt-Tg fly and mouse models. In
Drosophila, deletion of p53 provides strong protection
from neurotoxicity associated with the mHtt transgene.
The protection is specific, as expression of an anti-
apoptotic protein, p35, in the mHtt-Tg fly does not re-
verse its retinal degeneration (Jackson et al., 1998). In
mice, pharmacologic or genetic suppression of p53
in mHtt-Tg normalizes respiratory complex IV activity
in mitochondria and ameliorates several behavioral def-
icits typical of HD. Together, these results suggest that
p53 may modulate mitochondrial dysfunction, cell death,
and behavioral abnormalities associated with HD in vivo.p53 in Neurological Diseases
In summary, our study establishes a specific role for
p53 in HD. As p53 is a nuclear transcription factor that
regulates various mitochondrial genes and insofar as
mitochondrial dysfunction appears important in HD,
our findings provide a molecular mechanism linking
disturbances of nuclei and mitochondria in HD.
Molecular mechanisms of neurodegenerative dis-
eases are complex (Beal, 2001; McNaught et al., 2001).
Some neurological conditions display primary mito-
chondrial abnormalities. Mitochondrial malfunction and
proteasomal disturbances have been implicated in the
pathophysiology of Parkinson’s disease (PD) (Beal,
2001). As p53 is regulated by its proteolysis via the
ubiquitin/proteasome cascade, p53 may link proteaso-
mal and mitochondrial abnormalities in certain forms
of PD (Duan et al., 2002; Mandir et al., 2002). Though
controversial, p53 has been implicated in amyotrophic
lateral sclerosis (ALS) (Gonzalez de Aguilar et al., 2000;
Kuntz et al., 2000). p53 is upregulated in Angelman syn-
drome, a neurodevelopmental disorder in which E6-AP
ubiquitin ligase, which mediates p53 degradation, is
mutated (Jiang et al., 1998). p53 is a nodal protein acti-
vated and stabilized by diverse mechanisms, which in-
fluences numerous downstream molecules in a context-
dependent manner (Vogelstein et al., 2000). It may be
rewarding to analyze features of the p53 pathway
unique to each neurological disease as well as those
that are shared.
A lower incidence of cancer has been reported in HD
patients (Sorensen et al., 1999). As p53 is a tumor sup-
pressor, its upregulation in multiple HD tissues might
account for diminished carcinogenesis, though dietary
and other extrinsic factors in cancer incidence must be
ruled out (Kazemi-Esfarjani and Benzer, 2002).
Experimental Procedures
Reagents and Plasmids
Unless otherwise noted, reagents were obtained from Sigma. All
the Htt plasmids were previously described (Cooper et al., 1998).
pSuper-p53 plasmids were made as previously described (Brum-
melkamp et al., 2002). The targeting sequence of pSuper-p53 is the
coding regions 767–787 of R. norvegicus p53, AAGACTCCAGTGG
GAATCTTC (NM_030989), as PC12 cells were derived from rat. The
targeting sequence of pSuper-control is the coding regions 773–
793 of H. sapiens p53, AAGACTCCAGTGGTAATCTAC (NM_000546).
Immunoblotting, Co-IP, and In Vitro Binding
PC12 cells were harvested 6–8 days after the induction of Htt. For
subcellular fractionation (Figure 1A), cells were homogenized with
a glass-glass homogenizer (Wheaton) in 50 mM Tris-Cl buffer (pH
7.4) containing 0.32 M sucrose and protease inhibitor cocktail
(Roche). Homogenates were centrifuged for 10 min at 1000 × g
providing pellet (P1) and supernatant (S1). Protein concentration
was measured with BCA protein assay reagent (Pierce). Equal
amounts of protein were loaded and separated by SDS-PAGE. To
check if p53 protein level is differentially increased in SDS-soluble
or -insoluble fractions (Figure 1C), PC12 cells were homogenized
in 50 mM Tris-Cl buffer (pH 7.4), 1% Triton X-100, and protease
inhibitor cocktail. The homogenate was centrifuged for 30 min at
15,000 × g. The pellet was resuspended in 50 mM Tris (pH 7.4)
with 1% SDS and considered total protein. After boiling for 5 min,
samples were centrifuged at 1000 × g for 1 min. The loose pellet
was considered the SDS-insoluble fraction, and the supernatant
was considered the SDS-soluble fraction. Equal amounts of protein
were analyzed by SDS-PAGE and immunoblotting. p53 protein
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38levels were measured in brain tissues from 8-month-old line 6 mHtt t
itransgenic mice and HD patients of various Vonsattel grades (Fig-
ures 1D and 1E). For p53 positive control, wt mice received kainate d
P(35 mg/kg i.p.) and were sacrificed after 48 hr. Striatum was dis-
sected and used for immunoblotting. J.C. Troncoso provided hu- o
dman cerebral cortical, striatal, and cerebellar tissues (Vonsattel
grades 1–4) from HD patients and age-matched controls (three pa- p
ptients per grade). All brain tissues were homogenized in RIPA lysis
buffer (150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% e
cSDS, and 50 mM Tris-Cl, pH 8.0). The homogenate was put on ice
for 30 min and centrifuged for 10 min at 15,000 × g. The pellet was t
cresuspended in RIPA buffer and boiled for 5 min. Samples were
centrifuged at 1000 × g for 1 min, and the supernatant was used l
pfor immunoblotting. p53 (DO-1) and β-actin antibodies were from
Santa Cruz. For secondary antibody and detection, VECTASTAIN p
cElite ABC-Kit (Vector) and SuperSignal West Femto Substrate
(Pierce) were used according to the manufacturer’s protocol. p53 
ftargets were analyzed by immunoblotting using Apaf-1, Bax, and
Puma antibodies (Cell Signaling) from PC12 cells transiently trans- m
pfected with N171 Htt 90 hr after transfection (Figure 2F). To examine
mHtt and p53 protein levels in the cross-bred mice (Figure 6F), r
obrain samples were prepared from 4-month-old wt, p53−/−, mHtt-
Tg, and mHtt-Tg/p53−/− mice and immunoblotted with p53 (DO-1) m
cand Htt (EM48; Chemicon) antibodies. For co-IP of endogenous
mHtt and p53 (Figure 1I), p53 was immunoprecipitated from the c
RIPA lysates of HD patient lymphoblasts treated with 1 M stauro-
sporine for 24 hr, and Htt was immunoblotted by EM48. To evaluate M
the effect of polyQ expansion on the interaction (Figures 1G and C
1H), co-IP of Htt and p53 was performed in 293T cells transfected M
with Htt. DO-1, EM48, and rabbit polyclonal AP231 (Htt) antibodies f
were used. In vitro binding of His-tagged Htt and GST-p53 proteins (
was performed as previously described (Li et al., 2002). b
b
Reverse Northern Assay w
We spotted 1 g of DNAs corresponding to the open reading frame s
of p53, b-actin, zif268, Fos-B, and Siah genes onto a nitrocellulose o
membrane under the vacuum. The DNA samples were initially de- w
natured by high concentration of NaOH at 100°C for 5 min and then e
were applied onto a membrane using a Bio-Rad Bio-dot microfiltra- T
tion apparatus. Total mRNA was extracted from PC12 cells har- F
vested 6–8 days after the induction of Htt and was reverse tran- m
scribed with [32P]dCTP. The 32P-labeled cDNA mixtures were (
denatured by incubation at 94°C for 5 min and rapidly chilled on s
ice. The membrane with spotted genes was prehybridized with r
heat-denatured sheared salmon sperm DNA for 1–2 hr. Then, 32P- I
labeled cDNA probe was added to the membrane, incubated over- a
night at 60°C, and then washed in the next morning. Signals from r
the membrane were recorded on a phosphorimager. o
f
aCulture and Transfection of Primary Neocortical Neurons
E16–E18 primary neocortical cultures were prepared with mouse
embryos from p53+/− × p53+/− parents of C57BL/6 strain or V
Sprague-Dawley rat embryos. Because p53−/− female mice are F
sterile, we always crossbred p53+/− males with p53+/− females and 
cultured embryonic neurons individually without knowing the geno- t
type. Neurons were grown on poly-D-lysine-coated plates at 500 t
cells/mm2 in Neurobasal medium with B27 supplement and 0.5 mM c
L-glutamine (Invitrogen). On 5 DIV or earlier, neurons were trans- a
fected with DNA using Lipofectamine 2000 (Invitrogen) following w
the manufacturer’s protocol. Transfection efficiency was consis- a
tently 3%–5%, which was adequate for the neuron-based experi- 3
ments including p53 reporter assays. Transfection efficiency was i
decreased dramatically after 5 DIV, so transfection was always per- p
formed on 5 DIV or earlier. The ratio of plasmid to Lipofectamine e
2000 was 1:2.5. To do the experiments in a blinded manner, each f
mouse embryo from p53+/− × p53+/− parents was genotyped after r
all the analyses had been finished. w
pp53 Reporter Assay
All the cells used in p53 reporter assays with NGF-differentiated d
MPC12 cells and primary neurons were plated on 35 mm dishes at a
density of 106 cells/well and transfected within 5 days using 4 g G
rof DNA, 10 l Lipofectamine 2000, and 500 l of OPTI-MEM (Invi-rogen) per well. The p53 reporter contains a consensus p53 bind-
ng site followed by luciferase (el-Deiry et al., 1992). β-galactosi-
ase is under the control of a TK promoter. NGF-differentiated
C12 cells stably expressing Htt N63 were transfected with 3 g
f p53 reporter and 1 g of b-galactosidase after 1 day of Htt in-
uction (Figure 2A). 2 g of Htt N171-18Q or N171-82Q, 1.5 g of
53 reporter, and 0.5 g of b-galactosidase were added to the rat
rimary neurons (Figure 2B). The luciferase assay was sensitive
nough to detect differences in the 3%–5% transfected primary
ortical neurons. To compare the effects of Htt and ataxin-1 on p53
ranscriptional activity (Figure 2C), NGF-differentiated normal PC12
ells were transfected with 2 g of Htt N171-18Q, N171-82Q, full-
ength Htt with 23Q (FL-23Q), FL-82Q, ataxin-1-2Q, or ataxin-1-82Q,
lus 1.5 g of p53 reporter and 0.5 g of b-galactosidase. For the
ifithrin-α experiment (Figure 2E), NGF-differentiated normal PC12
ells were transfected with 2 g of Htt N171-18Q or N171-82Q, 1.5
g of p53 reporter and 0.5 g of b-galactosidase, and 1 M pi-
ithrin-α or DMSO was added simultaneously. For the RNAi experi-
ent (Figure 2E), PC12 cells were transfected with 1.2 g of
Super-control or pSuper-p53, 0.6 g of Htt N171, 0.15 g of p53
eporter, and 0.05 g of b-galactosidase, and harvested after 72 hr
f transfection. Luciferase activity was measured using the Pro-
ega Luciferase Assay System following the manufacturer’s proto-
ol and normalized to β-galactosidase activity or total protein con-
entration, both of which gave identical results.
itochondrial Depolarization Assay and Respiratory
hain Complex IV Activity Assay
itochondrial membrane potential was measured in lymphoblasts
rom the HD patients or control subjects as previously described
Sawa et al., 1999). Pifithrin-α (10 M) was added to the lympho-
lasts 24 hr before 25 M cyanide exposure. Mitochondrial mem-
rane potential of PC12 cells and primary neurons expressing Htt
as examined with JC-1 and Mitotracker (Molecular Probes), re-
pectively, following the manufacturer’s protocol. PC12 cells were
bserved using a Perkin Elmer UltraVIEW confocal microscope,
hile for primary neurons, a Zeiss Axiovert 135 microscope was
mployed. Exposure time was constant throughout the procedure.
o induce rapid mitochondrial depolarization in PC12 cells, 50 M
CCP was applied for 10 min after 5 min plasma membrane per-
eabilization by 0.01% w/v digitonin in 130 mM KCl, 5 mM HEPES
pH 7.0), and 5 mM glutamate. Each graph bar corresponds to the
coring of 500 PC12 cells or 1000 to 2000 primary neurons from
andomly chosen fields. Mitochondrial respiratory chain complex
V, cytochrome C oxidase, activity in mouse striatum was measured
s previously described (Tabrizi et al., 2000). Line 81 mHtt-Tg mice
eceived pifithrin-α (2 mg/kg i.p.) or DMSO daily from 2.5 months
f age. mHtt-Tg mice and age-matched control mice were sacri-
iced at 5 months of age. Striatum was dissected and used for the
ssay of cytochrome C oxidase activity.
iability Assay and Aggregate Formation Assay
or PC12 cells stably transfected with inducible Htt, pifithrin-α (1-10
M) was dissolved in DMSO and added directly to the medium at
he final concentration on the day of induction and every 3 days
hereafter (Figure 4A). For the RNAi experiment, differentiated PC12
ells on 35 mm dishes were transiently transfected with 1 g of Htt
nd 3 g of pSuper-p53 or pSuper-control (Figure 4A). Cell viability
as monitored using two fluorescent dyes for nuclear staining with
Zeiss Axiovert 135 inverted microscope: cell-permeable Hoechst
3258 (10 g/ml) to label total cells, and cell-impermeable propid-
um iodide (10 g/ml) for dead cells (Molecular Probes). Each ex-
eriment contained cells from ten randomly selected fields from
ach of two wells. The ratio of dead cells to total cells was used
or statistical analysis. The result is consistent with the previous
eport (Igarashi et al., 2003), in which a trypan blue exclusion assay
as used.
Neuronal death was quantified at 96 hr in a blinded manner as
reviously described (Nucifora et al., 2001). Briefly, cells with both
egenerated neurites and shrunken nuclei were considered dead.
orphology of neurites and nuclei was monitored, respectively, by
FP signal and Hoechst staining. Genotyping of each set of neu-
ons was performed after counting as described below. For mHtt
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39aggregate formation, N67-104Q-GFP was transfected into mouse
embryonic neurons. Nuclear and cytoplasmic aggregates were
scored after 2 days. Aggregates were visualized by GFP. Both
epifluorescent and bright-field images were taken from the same
field. Cellular compartmentalization was determined by overlaying
GFP, Hoechst, and bright-field images.
Drosophila Genetics
The flies used for the morphological analyses were reared on stan-
dard Drosophila medium at 25°C under a 12 hr light/12 hr dark
cycle. The wild-type flies used in this study were Canton S strain.
mHtt-Tg flies (pGMR:HttQ120) were described previously (Jackson
et al., 1998). The pGMR:HttQ120;P535A-1-4 flies were generated by
genetically introducing the Htt transgene into a P535A-1-4 back-
ground (Bloomington stock 6815). To assay the time course of reti-
nal degeneration, the mean number of rhabdomeres per ommatid-
ium was determined using the optical neutralization technique as
previously described (Xu et al., 2004). Each data point was based
on the examination of R100 ommatidia from at least five flies for
pGMR:HttQ120 and pGMR:HttQ120;P535A-1-4 flies, orR 80 ommatidia
from at least five flies for wild-type and P535A-1-4 flies.
Mouse Maintenance and Behavioral Assay
B6C3F1/J line 81 mHtt-Tg mice were genotyped as previously de-
scribed (Schilling et al., 1999). C57BL/6 p53+/− mice were pur-
chased from Taconic. The wild-type allele of p53 was genotyped
by PCR with 5#-GTGCAGTTGTGGGTCAGCGCCACACCTCCA-3#
and 5#-CTGTCTTCCAGATACTCGGGATAC-3# and knockout allele,
5#-TCGTGCTTTACGGTATCGCCGCTCCCGATT-3# and 5#-CTGTCTT
CCAGATACTCGGGATAC-3#. Two mHtt-Tg male mice were crossed
with four C57BL/6 p53+/− female mice to obtain mHtt-Tg/p53+/−
mice. Seven mHtt-Tg/p53+/− male mice were then backcrossed with
16 C57BL/6 p53+/− female mice. After the double cross-breeding, 17
wt, 28 p53−/−, 11 p53−/−, 6 mHtt-Tg, 17 mHtt-Tg/p53+/−, and 7 mHtt-
Tg/p53−/− mice were obtained. Only wt, p53−/−, mHtt-Tg, and mHtt-
Tg/p53−/− mice were chosen for the behavioral assays, because
p53+/− mice might show marked variation in protein expression
levels of posttranslationally regulated p53 in the brain. Onset of HD
behavioral symptoms occurs around 3 months in line 81 mHtt-Tg,
and robust tumorigenesis occurs after 6 months of age in p53−/−
mice (Donehower et al., 1992). All the behavioral analyses were
performed between 3 and 4 months of age. Open-field tests were
performed using a Versamax Animal Activity Monitoring System
(Accuscan) for 20 hr from 4 PM to 12 PM with a dark period from
6 PM to 6 AM. Acoustic startle and prepulse inhibition responses
were measured in a startle chamber (San Diego Instruments). The
protocol was as reported (Carter et al., 1999) except that prepulse
warnings of 2 and 4 dB above background noise and acoustic stim-
uli of 120 dB were adopted. Rotarod test was performed as pre-
viously reported (Schilling et al., 1999). Latency to clasping of the
hindlimbs was also measured.
Densitometry and Statistical Analysis
Quantitative densitometric measurement of immunoblotting and re-
verse Northern assay was performed using EagleSight program
(Stratagene). The results were quantified in arbitrary units, where 1
equals the level of control or wtHtt. Two-tailed p values were calcu-
lated by Student’s t test and one-way analysis of variance (ANOVA)
using Minitab 13. Values depicted are mean ± SEM.
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